Khiron Life Sciences Corp.
KHRNH.V
TSX
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 36.79% | 62.62% | 70.37% | 69.97% | 54.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.79% | 62.62% | 70.37% | 69.97% | 54.90% |
| Cost of Revenue | 384.61% | 702.99% | 981.14% | 637.40% | -55.24% |
| Gross Profit | -32.35% | -22.67% | -18.99% | -4.17% | 203.18% |
| SG&A Expenses | -13.75% | -11.68% | -2.84% | -5.63% | -15.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.10% | 21.67% | 26.67% | 12.85% | -22.35% |
| Operating Income | -1.84% | 0.35% | -6.75% | 6.70% | 42.21% |
| Income Before Tax | -93.65% | -62.81% | -74.79% | -50.22% | 43.24% |
| Income Tax Expenses | -519.49% | -706.38% | -669.97% | -636.34% | 1,226.42% |
| Earnings from Continuing Operations | -90.26% | -59.53% | -71.65% | -47.58% | 42.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.26% | -59.53% | -71.65% | -47.58% | 42.94% |
| EBIT | -1.84% | 0.35% | -6.75% | 6.70% | 42.21% |
| EBITDA | 0.18% | 3.67% | -3.55% | 9.35% | 44.11% |
| EPS Basic | -57.83% | -20.45% | -24.88% | -3.24% | 56.22% |
| Normalized Basic EPS | 16.05% | 34.44% | 26.43% | 37.90% | 58.27% |
| EPS Diluted | -54.00% | -16.05% | -19.97% | -3.30% | 55.43% |
| Normalized Diluted EPS | 16.05% | 34.44% | 26.43% | 37.90% | 58.27% |
| Average Basic Shares Outstanding | 24.66% | 31.31% | 33.22% | 36.71% | 30.63% |
| Average Diluted Shares Outstanding | 24.66% | 31.31% | 33.22% | 36.71% | 30.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
